Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Performance Testing and External Validation of an AI Algorithm to Detect and Segment Brain Metastases.

Neuro-oncology·2026
Same author

Feasibility and utility of a tablet-based digital neurocognitive assessment following radiosurgery for brain metastases.

Scientific reports·2026
Same author

Patterns of Failure After Definitive Ablative 5-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Ductal Adenocarcinoma.

International journal of radiation oncology, biology, physics·2026
Same author

Quantifying risk of radiation necrosis: Normal tissue complication probability modeling following stereotactic radiosurgery for small brain metastases in the modern era.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Evaluating the efficacy of a federated AI algorithm in assisting in the detection and segmentation of brain metastases: limitations and opportunities.

Journal of neuro-oncology·2025
Same author

Initial three- and half-year machine performance assessment of a superficial radiation therapy unit.

Journal of applied clinical medical physics·2025

Related Experiment Video

Updated: Jun 7, 2026

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement
06:33

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement

Published on: July 29, 2013

QA procedures for multimodality preclinical tumor drug response testing.

Yongsook C Lee1, Beth A Goins, Gary D Fullerton

  • 1Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA.

Medical Physics
|October 23, 2010
PubMed
Summary

Standardized quality assurance procedures using a novel phantom improve the accuracy of tumor size measurements for preclinical cancer drug testing. This ensures reliable data across multiple institutions and imaging modalities.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Experiment Videos

Last Updated: Jun 7, 2026

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement
06:33

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement

Published on: July 29, 2013

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Area of Science:

  • Preclinical cancer research
  • Biomedical imaging
  • Drug development

Background:

  • Imaging biomarkers accelerate preclinical anticancer drug testing in rodent models.
  • Current FDA-approved biomarkers (e.g., WHO, RECIST) rely on tumor size measurements.
  • Multi-center, multi-modality studies risk compromised data due to measurement variability.

Purpose of the Study:

  • Develop standardized quality assurance (QA) procedures for preclinical tumor response assessment.
  • Validate accuracy of tumor size measurements using a multimodality phantom.
  • Ensure reliable evaluation of cytostatic drugs in cancer research.

Main Methods:

  • A phantom with five low-contrast objects simulating animal tumors was created using tissue-mimicking materials.
  • Phantom imaging was conducted across three modalities (ultrasound, CT, MRI) at two institutions.
  • Tumor size measurements were evaluated for accuracy and precision.

Main Results:

  • A single phantom is effective for multi-modality imaging QA.
  • The phantom successfully validated the precision and accuracy of tumor size measurements.
  • Data from ultrasound, computed tomography, and magnetic resonance imaging were assessed.

Conclusions:

  • Standardized QA procedures using the phantom ensure data integrity.
  • This approach identifies and excludes unreliable data from poorly maintained instruments or operator error.
  • The phantom supports accurate and reproducible tumor response assessment in multi-institutional trials.